NextCure, Inc. develops targeted cancer therapies as a clinical-stage biopharmaceutical company, with news centered on antibody-drug conjugate programs and related financial updates. Its principal update themes include SIM0505, a Cadherin-6-directed ADC with a topoisomerase 1 inhibitor payload, and LNCB74, a B7-H4-directed ADC.
Company announcements also cover clinical data presentations, FDA interactions such as Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, collaborations with Simcere Zaiming, business updates, financial results, and participation in healthcare investor conferences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its presentation at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 10:15 am ET. The event will include a live audio webcast accessible through the company's website, with a replay available for 30 days afterward. NextCure focuses on developing novel immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform. The company aims to address unmet medical needs for patients unresponsive to existing therapies. This announcement comes amidst discussions about the company's growth strategies and future prospects in the biopharmaceutical market.